JPM vs MYI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MYI presents as a stable but stagnant closed-end fund, evidenced by a Piotroski F-Score of 5/9 and a Price-to-Book ratio of 0.90, indicating it trades at a 10% discount to its net asset value. While the current price of $10.76 sits comfortably between the Graham Number ($10.09) and Intrinsic Value ($11.21), the fund exhibits a critical sustainability issue with a payout ratio of 175.26%. The extreme earnings growth figures are likely accounting anomalies rather than organic growth. Overall, the fund is a value play for income seekers, but the bearish technical trend and unsustainable distribution profile limit upside potential.
Compare Another Pair
Related Comparisons
JPM vs MYI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and BlackRock MuniYield Quality Fund III, Inc. (MYI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.